The benefits of valsartan (Val)/hydrochlorothiazide (HCTZ) combination as initial treatment for hypertension were evaluated in a post hoc analysis of an 8-week, doubleblind, placebo-controlled, parallel-group trial. The highest dose of Val/HCTZ combination (320/25 mg), component monotherapies (Val 320 mg, HCTZ 25 mg) and placebo were selected for this analysis (N ¼ 675, 52.1% men, 68.6% Caucasians, mean age 52.9 years, baseline blood pressure (BP) 150.6/99.1 mm Hg). As soon as 2 weeks after initiation of active therapy, greater BP control rates were observed with Val/HCTZ (320/25 mg) compared with Val (320 mg), HCTZ (25 mg) and placebo. Similar results were observed in subgroups of patients with stage 1 and stage 2 hypertension, as well as in diabetic patients. As baseline BP increased, the probability of achieving mean sitting systolic BP (o140 and o130 mm Hg) and mean sitting diastolic BP control (o90 and o80 mm Hg), determined using a logistic regression model, decreased with all treatments. However, at all levels of baseline BP, the probability of achieving BP control was greater with Val/HCTZ combination. The Val/HCTZ combination was well tolerated with overall incidence of adverse events similar to that observed with monotherapy and placebo. These results support the use of Val/HCTZ combination as initial therapy in hypertensive patients unlikely to achieve BP control with a single agent.
Introduction
Inadequate control of blood pressure (BP) is a major predisposing factor for cardiovascular (CV) disease. With the number of adults suffering from elevated BP anticipated to increase to 1.56 billion worldwide by 2025, hypertension poses a major challenge to public health. 1 Current guidelines are in agreement that aggressive therapy is required to reduce CV morbidity and mortality in patients with significantly elevated BP. [2] [3] [4] [5] [6] It is recommended that consideration be given to initiating therapy with two drugs for patients with systolic/diastolic BP (SBP/DBP) 420/10 mm Hg above target goal, thereby increasing the likelihood of achieving goal BP in a timely manner. 2, 5 This recommendation is supported by the fact that there is a o5% chance of decreasing DBP 412 mm Hg with a single antihypertensive agent. 7 Even if patients' BP are initially controlled by a single agent, additional agents may need to be added to maintain control over time. In the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), B63% of patients were treated with two or more antihypertensive agents at the end of 5 years of follow-up. 8 Not only is adequate BP control critical, the time taken to achieve this goal is also important. The longer a patient experiences higher levels of BP, the greater the risk for restructuring and remodelling of vascular beds with subsequent stiffening and loss of compliance. 9, 10 These pathophysiological changes can ultimately interfere with normal vasorelaxation processes, which may be important in the reduction of BP, particularly over the long term. 11, 12 In addition, rapid BP reduction also leads to a reduction in the associated CV events. [13] [14] [15] Finally, one must consider the potential impact of initial combination therapy in a clinical practice setting. There is a strong relationship between the number of medication changes during the first 6 months of antihypertensive treatment and compliance rates during the subsequent 6 months of therapy. The longer it takes to reach BP control, the lower the compliance with time. 16 Therefore, initial combination therapy may improve long-term compliance in clinical practice with potentially improved outcomes.
Understanding the relationship between baseline BP and the probability of achieving BP control with either monotherapy or combination therapy would enable physicians to better evaluate the benefit and risk of initiating treatment with combination therapy. Recent studies have shown that the combination of an angiotensin receptor blocker, such as valsartan (Val), with the diuretic hydrochlorothiazide (HCTZ), has enhanced efficacy compared with component monotherapies and is well tolerated in hypertensive patients. [17] [18] [19] [20] This report describes the results of post hoc analyses designed to evaluate the benefit:risk profile of initial combination therapy with Val/HCTZ compared with monotherapy with Val or HCTZ and placebo by assessing efficacy as a function of baseline BP.
Methods

Study design
This was a post hoc analysis of an 8-week, randomized, double-blind, placebo-controlled, multifactorial, parallel-group trial. Complete details of the study have been published previously. 17 A total of 1652 patients were enrolled into the single-blind period of the study, and 1346 patients with a mean sitting DBP (MSDBP) X95 and o110 mm Hg were randomly allocated into the double-blind treatment phase. The study assessed the antihypertensive efficacy and tolerability of once-daily dosing of Val/HCTZ combination therapy (160/12.5, 320/12.5 and 320/25 mg) compared with Val (160 and 320 mg), HCTZ (12.5 and 25 mg) and placebo. Patients randomized to Val/HCTZ were initiated on combination therapy. During the first week after randomization, patients in the Val/HCTZ 320/12.5 and 320/25 mg treatment groups received Val/HCTZ 160/12.5 mg, whereas patients randomized to the remaining six treatment groups received their respective final doses. From the second postrandomization week (week 1) through the end of the trial (week 8), all treatment groups received their final dose. These analyses included the safety information of all available doses. The efficacy analyses focused strictly on the highest dose of the Val/HCTZ combination (320/25 mg) along with the respective highest doses of component monotherapies (Val 320 mg or HCTZ 25 mg), as the efficacy and safety profile of the maximum doses of monotherapy would influence the decision-making process of initiating therapy with the combination.
Efficacy
The overall BP control rates o140/90 mm Hg were assessed every 2 weeks in the intent-to-treat population and in subgroups of patients with stage 1 (mean sitting SBP (MSSBP) X140 and o160 mm Hg and/or MSDBP X90 and o100 mm Hg) and stage 2 (MSSBP X160 and/or MSDBP X100 mm Hg) hypertension.
BP control rates o130/80 mm Hg were also assessed in the overall population and in the subgroup of patients with diabetes. The percentage of patients achieving SBP (o140 and o130 mm Hg) and DBP (o90 and o80 mm Hg) control at end point was predicted as a function of baseline BP.
Safety
Safety was assessed by evaluating the incidence of adverse events (AEs), serious AEs and AEs leading to discontinuation in the safety population, defined as all randomized patients who had received at least one dose of the study drug.
Statistical analysis
All efficacy analyses were performed post hoc on the intent-to-treat population, defined as all randomized patients who had a baseline BP measurement and at least one post-baseline efficacy measurement. SBP and DBP control rates were analyzed in the intent-to-treat population at end point, using a logistic regression model with treatment as a factor and baseline BP as a covariate. End point was defined as measurement at week 8, or the last postbaseline observation was carried forward as the end point measurement. Summary statistics were performed for control rates at each biweekly visit for the intent-to-treat population and also for the subgroups of patients with diabetes and stage 1 and stage 2 hypertension. Two-dimensional line plots and predicted values of SBP and DBP control rates relative to baseline were generated for the Val/HCTZ 320/25 mg combination, component monotherapies (Val 320 mg; HCTZ 25 mg) and placebo. To keep a single curve for each treatment across all centres, the region factor was excluded from the logistic regression model for the plots and predicted control rates. Patients with baseline MSSBP o140 mm Hg, MSSBP o130 mm Hg, MSDBP o90 mm Hg and MSDBP o80 mm Hg were excluded from the respective control rate analyses using the same criteria.
Results
Patient population
The complete details of the patient disposition for the entire study have been published previously. 17 Of the 675 patients included in the Val/HCTZ 320/25 mg, Val 320 mg, HCTZ 25 mg and placebo groups, 568 (84.2%) completed the study. Study discontinuation rates in the Val/HCTZ 320/25 mg, Val 320 mg, HCTZ 25 mg and placebo groups were 10.1, 19.4, 15.0 and 18.9%, respectively. Discontinuations due to unsatisfactory therapeutic effect were 1.2, 2.9, 6.6 and 10.7%, respectively.
Treatment groups were well balanced for baseline demographics, disease characteristics and number of patients. 17 Of the patients in this post hoc data set, a total of 352 (52.1%) patients were men, 463 (68.6%) were Caucasian and 62 (9.2%) were diabetic. The mean age of the study population was 52.9 years with 102 (15.1%) patients X65 years of age. MSSBP and MSDBP were 150.6 and 99.1 mm Hg, respectively.
BP control in overall population by week Val/HCTZ combination therapy resulted in greater BP control rates compared with both HCTZ and Val monotherapies and placebo, as early as 2 weeks after starting therapy and continuing through the final week (Figures 1a and b (Figure 2a) . These results were observed consistently throughout the study period, including study end point (Val/HCTZ 62.1%; Val 31.7%; HCTZ 33.8%; placebo 21.1%). A similar pattern was observed in stage 1 patients (Figure 2b ), but the relative differences between the Val/HCTZ combination and the monotherapies were greater for stage 2 patients than for stage 1 patients. Prediction of systolic and diastolic control rates as a function of baseline BP Results of logistic regression models generated to predict SBP and DBP control rates at end point as a function of baseline BP are shown in Figure 3 . As expected, as baseline BP increased, the probability of achieving MSSBP and MSDBP control decreased regardless of therapy. Irrespective of the baseline BP, however, the probability of achieving an MSSBP o140 mm Hg and MSDBP o90 mm Hg was greater with combination therapy than with monotherapies and placebo (Figures 3a and b) . For example, the probability of achieving an MSSBP o140 mm Hg for a patient with a baseline MSSBP between 160 and 170 mm Hg was 77.1% with Val/HCTZ 320/25 mg, 32.4% with Val 320 mg and 39.6% with HCTZ 25 mg.
As expected, with more aggressive criteria of MSSBP o130 mm Hg and MSDBP o80 mm Hg, the probability of achieving control was less with each therapy compared with the less stringent criteria of o140 and o90 mm Hg, respectively. Nevertheless, even with the more aggressive criteria of MSSBP o130 mm Hg and MSDBP o80 mm Hg, the probability of attaining BP control was greater with combination therapy compared with monotherapy regardless of baseline BP (Figures 3c and d) . For example, the probability of achieving an MSSBP o130 mm Hg for a patient with a baseline MSSBP between 160 and 170 mm Hg was 38.8% with Val/ HCTZ 320/25 mg, 10.4% with Val 320 mg and 9.7% with HCTZ 25 mg.
Tolerability of initial therapy
The overall incidence of AEs regardless of study drug relationship in patients initiated on combination therapy was generally similar to that observed in those treated with monotherapy and placebo ( Table 1 ). The frequency of dizziness was dose dependent within the monotherapy and combination groups; however, the incidence with Val/HCTZ 160/12.5 mg was similar to that observed with Val 320 mg and HCTZ 25 mg. Discontinuations due to AEs ranged from 3.0 to 4.2% in the Val/HCTZ combination treatment groups compared with 2.4% in the placebo group. Six (1.2%) patients receiving Val/HCTZ and one (0.6%) patient receiving Val 320 mg discontinued therapy owing to hypotension or orthostatic hypotension. Three (0.6%) patients receiving Val/HCTZ, one (0.6%) receiving Val 320 mg and one (0.6%) receiving placebo discontinued therapy because of 
Discussion
This post hoc analysis of a randomized, doubleblind, placebo-controlled, multifactorial, parallelgroup study showed that initial therapy with the dual combination of Val/HCTZ produced an B1.5-fold greater number of patients (74.9% vs 48.8 and 51.8%) achieving a target BP of o140/90 mm Hg and a three-fold greater number of patients (30.5% vs 10.8 and 9.2%) achieving a more aggressive target BP of o130/80 mm Hg compared with Val or HCTZ monotherapies. This enhanced efficacy with initial combination therapy was observed as early as 2 weeks after starting therapy and the combination was well tolerated compared with monotherapy. Furthermore, the probability of achieving BP goal was greater with combination therapy irrespective of baseline BP.
These results provide important comparative data for practicing physicians in determining whether initial therapy is appropriate for a given patient. For patients with lower baseline BP, both Val and HCTZ monotherapy provided good BP control in the majority of patients. For patients with higher baseline BP, reaching goal with monotherapy was less likely and the benefit of Val/HCTZ combination relative to monotherapy was even more evident with greater treatment differences in BP goal rates and BP reductions. These data are consistent with the current Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high BP, as well as the updated ESH/ ESC (European Society of Hypertension/European Society of Cardiology) hypertension treatment guidelines, which recommend initial therapy with two drugs in patients with SBP levels 420 mm Hg above goal or DBP level 410 mm Hg above goal or in patients at high CV risk because of the presence of target organ damage, diabetes, renal disease or a history of CV disease. 2, 21 As hypertension is a multifactorial disease, disruption of a single physiological mechanism is often insufficient to control BP. Indeed, only 40-50% of patients treated with monotherapy, which target a single physiological pathway, have been reported to achieve goal BP. Therefore, a combination of two drugs with different, but complementary, modes of action is supported by hypertension guidelines to achieve effective BP control. 2, 5, 22, 23 In fact, our data suggest that select patients with higher baseline BP may require the addition of a third agent. Indeed, the need for three agents in combination to reach target goals has been demonstrated by several large-scale trials. 8, [24] [25] [26] In moderate and severe hypertensive patients, triple therapy with the combination of amlodipine/Val/HCTZ has been shown to produce significantly greater BP reductions than dual therapy with amlodipine/Val, Val/HCTZ or amlodipine/ HCTZ. 27 In a previously reported study by Calhoun et al., 28 the primary objective was to compare initial therapy with Val/HCTZ combination therapy with Val monotherapy in patients with severe hypertension. Patients initiated therapy with either Val 160 mg or Val/HCTZ 160/12.5 mg and were force-titrated to Val 320 mg and Val/HCTZ 320/25 mg, respectively. At the end of the 6-week study, significantly more patients achieved BP control and had greater BP reductions with combination therapy than with monotherapy. BP control rates were also greater with the combination regimen as early as 2 weeks after initiating therapy. This prompt reduction in BP with the combination of Val/HCTZ was observed in our current post hoc analyses. Several large clinical studies have shown that prompt BP reduction is associated with a reduced risk of CV and All randomized patients who had received at least one dose of study drug.
Rapid BP control with Val/HCTZ initial therapycerebrovascular complications and death. [13] [14] [15] In addition, the prompt and aggressive reduction of BP may have an important role in the subsequent antihypertensive response to the addition of other agents. For example, in SCOPE (Study on Cognition and Prognosis in the Elderly) and the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm) trial, the treatment group that had a smaller initial BP reduction failed to achieve BP reduction compared with the other treatment group in the long term, despite the addition of other antihypertensive agents to achieve target BP. 14, 29 Despite the need to achieve a prompt reduction in BP in patients with higher baseline BP, physicians are reluctant to prescribe higher doses of monotherapy or combination therapy because of potential adverse effects. This hesitancy by physicians to change and/or intensify treatment is often referred to as therapeutic or clinical inertia. 30, 31 Initiating therapy with monotherapy with subsequent dose escalations that require multiple office visits may result in a loss of compliance as well as a patient's confidence in the treatment plan. The updated ESH/ ESC guidelines favour the use of combination of two antihypertensive agents in a single pill, as reducing the number of pills results in improved compliance. 21, 32 Thus, using a single pill combination of Val/HCTZ would be a valuable first treatment step in patients with either high initial BP or those at high CV risk requiring a lower BP target. The availability of different dose combinations of the same two drugs further facilitates and simplifies the approach of a single pill combination therapy for management of hypertension.
Initial therapy with Val/HCTZ was well tolerated in the overall population in the current study. The combination did not present any additional safety concerns compared with monotherapy and the risks were manageable. Hypokalaemia associated with higher doses of HCTZ was attenuated with the co-administration of Val and HCTZ as reported previously. 17 A limitation to this report is the fact that the efficacy analyses were not pre-specified and the clinical trial was not specifically designed to address the objectives of this report. The probability estimates of reaching goal are less reliable at higher baseline BPs because of the small numbers of patients in this range. The 8-week double-blind period of the trial limits the predictive value on longer-term therapy. Another limitation was the lack of a formal analysis of compliance or adherence to the treatment regimen.
In summary, patients with higher levels of BP, for example, stage 2 hypertension, are at greater risk for adverse clinical outcomes. Practicing physicians must evaluate whether initiating dual combination therapy is warranted on an individual patient basis based on baseline BP, the likelihood of achieving goal with monotherapy compared with combination therapy and the individual patient's goal BP that is based on their CV risk profile. Data from our analyses support the favourable benefit:risk profile of Val/HCTZ as initial therapy in patients likely to need multiple drugs to achieve BP goal. The subsequent addition of a third agent may be required in select patients.
Conclusions
Initial therapy with the dual combination of Val/ HCTZ allowed a greater number of patients to achieve goal BP compared with both Val and HCTZ monotherapies. Greater efficacy with the dual combination was observed as early as 2 weeks after starting therapy. Initiating therapy with Val/HCTZ was well tolerated compared with monotherapy. Furthermore, the probability of achieving BP goal was greater with combination therapy irrespective of baseline BP or target BP goal. Initiating antihypertensive therapy with Val/HCTZ is an appropriate therapeutic option in patients likely to need multiple drugs to achieve BP goal.
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